Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. The specific reason for the cause of cholangiocarcinoma is not known as of yet. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and  may sometimes affect gall bladder as well. The significant symptoms of  cholangiocarcinoma includes jaundice, weight reduction, loss of hunger, blood in stool and urine, stomach pain, fever, and itching.

The global cholangiocarcinoma market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % during the forecast period (2021-2028).

Figure 1.Global Cholangiocarcinoma Market Share (%) in Terms of Value, By Treatment Type, 2021

Cholangiocarcinoma  | Coherent Market Insights

Increasing prevalence of cholangiocarcinoma is expected to drive the market growth during the forecast period.

Increasing prevalence of cholangiocarcinoma is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, according to American Cancer Society’s 2018 report, around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma to each year. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.

Figure 2.Global Cholangiocarcinoma Market Share (%), By Distribution Channel, 2021

Cholangiocarcinoma  | Coherent Market Insights

Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as acquisition which are expected to drive the market growth during the forecast period.

key companies are focusing on inorganic strategies such as acquisition in order to strengthen their products presence and this is expected to create a conductive environment for growth of the Cholangiocarcinoma market. For instance, in January 2021, Servier, a global pharmaceutical company, announced the acquisition of Agios Pharmaceuticals company’s commercial, clinical, and research-stage oncology portfolio which includes Tibsovo (ivosidenib tablets) for treatment of Cholangiocarcinoma and others.

request-sample

Cholangiocarcinoma Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 185.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2021 to 2028 CAGR: 12.8% 2027 Value Projection: US$ $ 429.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type:
    • Chemotherapy: Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5 fluorouracil (5-FU)
    • Targeted Therapy: Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)
    • Immunotherapy: 
      • Pembrolizumab (Phase 3)
    • Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.

Growth Drivers:
  • Increasing Prevalence of Cholangiocarcinoma
  • Increasing Drug Approvals and Launches
Restraints & Challenges:
  • High Cost of Cholangiocarcinoma and Cancer Treatment
  • Time-consuming Approach to Approving New Drugs

Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 143 million infected individuals worldwide as of April 21st 2021.

COVID-19 affects the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs. For instance, In April 2020, Chinese suppliers stopped supplies to India due to non-availability of labour, containers are piling up and all space is occupied. The incoming vessels will not be able to offload the containers and may bypass that result in the shortage of medicines in India.

Furthermore, players operating in the global cholangiocarcinoma market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges includes supply of raw materials (due to irregularities in transportation), which are required for manufacturing drug formulations. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Cholangiocarcinoma Market: Restraint

The major factors that hinder growth of the global cholangiocarcinoma market includes high cost of cholangiocarcinoma and cancer treatments and the time-consuming approach for approving new drugs.

Key Players

Major players operating in the global cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.

Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.

Market Dynamics

Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.

Key features of the study:

  • This report provides an in-depth analysis of the global cholangiocarcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cholangiocarcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

  • Global Cholangiocarcinoma Market, By Treatment Type:
    • Chemotherapy
      • Gemcitabine
      • Cisplatin
      • Oxaliplatin
      • Capecitabine
      • 5 fluorouracil (5-FU)
    • Targeted Therapy
      • Pemigatinib
      • Infigratinib (Phase 3)
      • Ivosidenib (Phase 3)
    • Immunotherapy
      • Pembrolizumab (Phase 3)
    • Others
  • Global Cholangiocarcinoma Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Cholangiocarcinoma Market, By Region:
    • North America
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Capecitabine
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • , By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Incyte Corporation*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Eisai Co., Ltd.
    • QED Therapeutics, Inc.
    • Agios Pharmaceuticals, Inc.
    • RenovoRx
    • Ability Pharmaceuticals
    • Imbrium Therapeutics L.P.
    • Delcath Systems, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • Brand Analysis
  4. Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Cholangiocarcinoma Market, By Treatment Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
        • Gemcitabine
        • Cisplatin
        • Oxaliplatin
        • Capecitabine
        • 5 fluorouracil (5-FU)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
          • Pembrolizumab (Phase 3)
    • Others
  6. Global Cholangiocarcinoma Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Online Pharmacies
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Cholangiocarcinoma Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries/Region, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Incyte Corporation
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Eisai Co., Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • QED Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Agios Pharmaceuticals, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • RenovoRx
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Ability Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Imbrium Therapeutics L.P.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Delcath Systems, Inc
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  9. Section
    • Research Methodology
    • About us

*Browse 27 market data tables and 31 figures on "Global Cholangiocarcinoma Market” - Global forecast to 2028

Frequently Asked Questions

The global cholangiocarcinoma market size is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % between 2021 and 2028.
Factors such as increasing prevalence of cholangiocarcinoma and increasing drug approvals and launches are expected to drive the market growth during the forecast period.
Chemotherapy segment is expected to hold a major market share during the forecast period in treatment type segment.
The major factors hampering growth of the market includes high cost of cholangiocarcinoma and cancer treatments.
Major players operating in the market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner